Genetics and Epigenetics in Complex Diseases

doi:10.3390/books978-3-0365-7856-9

Download Url(s)

https://mdpi.com/books/pdfview/book/7398

Contributor(s)

Lopez-Lopez, Elixabet (editor)

Language

English

Show full item record

Abstract

Many of the most common diseases are influenced by a combination of multiple factors, which include environmental effectors as well as genetic and epigenetic variations. Therefore, these diseases are grouped under the term “complex” diseases because, from the point of view of genetics, they cannot be explained by simple Mendelian inheritance. The aim of this special issue was to identify genetic and epigenetic factors involved in such diseases in order to improve not only the knowledge of risk factors for those diseases, which could be of help for prevention, but also the understanding and characterization of each disease and to optimize and personalize the treatment.

URI

https://directory.doabooks.org/handle/20.500.12854/101305

Keywords

chromatin remodeling; circular RNA; DNA methylation; histone modification; non-coding RNA; oncogenes; tumor suppressor genes; tumor virus; chronic lymphocytic leukemia; CLL; SF3B1 mutation; NOTCH; IKAROS; syncope; vasovagal syncope; genetics; complex disorders; susceptibility; twin studies; family studies; candidate gene association studies; genome-wide studies; acute myeloid leukemia; pediatric; trio sequencing; germline cancer predisposition; POT1; shelterin complex; psoriasis; psoriatic arthritis; NF-κB; comorbidities; genetic architecture; SKP1; CUL1; RBX1; SKP2; FBXW7; FBXO5; SCF complex; genome instability; chromosome instability; cancer; VDBP; vitamin D binding protein; rs7041; rs4588; bone density; diabetes; obesity; COPD; pulmonary tuberculosis; SNP; MD; PD; CD33; Alzheimer’s disease; sialic acid; phagocytosis; KLF14; body shape indices; metabolic traits; differential effect; genetic variants; resistin; soluble suppression of tumorigenicity 2; weighted genetic risk score; Taiwan Biobank; coronary artery disease; all-cause mortality; major adverse cardiac events; acute lymphoblastic leukemia; RAD21; cohesin complex; n/a